An estimated 15-20 million people worldwide live with hepatitis delta virus co-infection, representing a substantial global health burden that has historically lacked effective therapeutic interventions. These patients experience disease progression 2-6 times faster than those with hepatitis B mono-infection, with heightened risk for cirrhosis, liver failure, and hepatocellular carcinoma.
Hepatitis delta virus functions as a satellite pathogen, capable of replicating only in the presence of hepatitis B virus, creating a uniquely aggressive clinical phenotype. The newly FDA-approved Hepcludex offers the first pharmacologic treatment option specifically designed to suppress viral replication in this vulnerable population. This approval represents a pivotal shift in hepatology practice, providing clinicians with evidence-based therapy for patients who previously had no disease-modifying treatment options available.
The significance of this approval extends beyond symptomatic management, offering potential to alter disease trajectory for millions of affected patients globally. Read the full article on GMJ Newsroom.
Was this article helpful?
